KalVista Pharmaceuticals
KALV
KALV
130 hedge funds and large institutions have $467M invested in KalVista Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 50 increasing their positions, 29 reducing their positions, and 19 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more funds holding in top 10
Funds holding in top 10: →
0.34% less ownership
Funds ownership: 112.01% → 111.68% (-0.34%)
17% less capital invested
Capital invested by funds: $561M → $467M (-$93.5M)
94% less call options, than puts
Call options by funds: $115K | Put options by funds: $1.8M
Holders
130
Holding in Top 10
4
Calls
$115K
Puts
$1.8M
Top Buyers
| 1 | +$11.6M | |
| 2 | +$10.2M | |
| 3 | +$8.41M | |
| 4 |
VPC
Vestal Point Capital
New York
|
+$6.52M |
| 5 |
SCM
Suvretta Capital Management
New York
|
+$5.94M |
Top Sellers
| 1 | -$10.4M | |
| 2 | -$9.48M | |
| 3 | -$4.11M | |
| 4 |
BlackRock
New York
|
-$1.68M |
| 5 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
-$858K |